The present invention relates to polypeptide fragments capable of raising a specific T-cell response, wherein said fragment comprises a peptide consisting of at least 9 consecutive amino acid residues of ML-IAP as well as to said fragments for use as medicaments. The invention furthermore relates to use of said polypeptide frag-ments in the manufacture of a medicament for treatment of a clinical condition, such as cancer. The invention also relates to methods of selecting a peptide comprising a fragment of ML-IAP for use in a vaccine composition as well as to vaccine composi-tions comprising isolated ML-IAP (SEQ ID NO:1) and/or one or more fragments thereof.